These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 33777757)

  • 1. Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade.
    Lei Y; Li X; Huang Q; Zheng X; Liu M
    Front Oncol; 2021; 11():617335. PubMed ID: 33777757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy.
    Sun S; Xu L; Zhang X; Pang L; Long Z; Deng C; Zhu J; Zhou S; Wan L; Pang B; Xiao Y
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33915876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.
    Xu Y; Zuo F; Wang H; Jing J; He X
    Front Immunol; 2022; 13():1045957. PubMed ID: 36389711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.
    Xiao Q; Nobre A; Piñeiro P; Berciano-Guerrero MÁ; Alba E; Cobo M; Lauschke VM; Barragán I
    J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31968651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
    Music M; Prassas I; Diamandis EP
    Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.
    Tray N; Weber JS; Adams S
    Cancer Immunol Res; 2018 Oct; 6(10):1122-1128. PubMed ID: 30279188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
    Zhongqi F; Xiaodong S; Yuguo C; Guoyue L
    Anticancer Agents Med Chem; 2019; 19(2):222-228. PubMed ID: 30426903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Aging and Immunotherapy in Cancer.
    Kaiser M; Semeraro MD; Herrmann M; Absenger G; Gerger A; Renner W
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
    Chen K; Ye H; Lu XJ; Sun B; Liu Q
    Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of DNA repair defects in predicting immunotherapy response.
    Zhang J; Shih DJH; Lin SY
    Biomark Res; 2020; 8():23. PubMed ID: 32612833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects.
    Li T; Liu T; Zhu W; Xie S; Zhao Z; Feng B; Guo H; Yang R
    Clin Med Insights Oncol; 2021; 15():11795549211035540. PubMed ID: 34408525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of immune checkpoint inhibition in the treatment of ovarian cancer.
    Gaillard SL; Secord AA; Monk B
    Gynecol Oncol Res Pract; 2016; 3():11. PubMed ID: 27904752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosting Checkpoint Immunotherapy with Biomaterials.
    Liu L; Pan Y; Zhao C; Huang P; Chen X; Rao L
    ACS Nano; 2023 Feb; 17(4):3225-3258. PubMed ID: 36746639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction.
    Wei H; Jiang H; Song B
    Cancer Med; 2019 Sep; 8(12):5399-5413. PubMed ID: 31385454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
    Nishino M; Ramaiya NH; Hatabu H; Hodi FS
    Nat Rev Clin Oncol; 2017 Nov; 14(11):655-668. PubMed ID: 28653677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
    Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
    House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
    Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.